Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| S412003-100μg | 100μg | In stock | $39.90 | |
| S412003-1mg | 1mg | In stock | $159.90 | |
| S412003-5mg | 5mg | In stock | $664.90 | |
| S412003-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,196.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Sarilumab (anti-IL-6Rα), for Flow,ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR) various applications, specific to IL6R, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | Sarilumab; SAR153191; REGN88; CD 126 antibody; CD126 antibody; CD126 antigen antibody; gp80 antibody; IL 6R 1 antibody; IL 6R alpha antibody; IL 6R antibody; IL-6 receptor alpha chain antibody; IL-6 receptor subunit alpha antibody; IL-6R 1 antibody; IL-6R |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | IL6R |
| Application | Flow,ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | ANTAGONIST |
| Mechanism of action | Antibody of Interleukin-6 receptor; α subunit |
| Product Description | Sarilumab is a human immunoglobulin G1 monoclonal antibody. Sarilumab is an antagonist of the interleukin-6 IL-6 receptor. Sarilumab has a high affinity for the IL-6 receptor and inhibits both cis-and trans-signaling of IL-6, reducing inflammation. Sarilumab can be used in rheumatoid arthritis studies. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Light Chain Type | kappa |
| SDS-PAGE | 27.0 kDa (Light Chain) & 51.9 kDa (Heavy Chain), under reducing conditions; 186.5 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1189541-98-7 |
Sarilumab (anti-IL-6Rα) (S412003) - Flow Cytometry
Flow Cytometry analysis of U937 cells labelling IL-6Rα (red) with Sarilumab (anti-IL-6Rα) (S412003). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Sarilumab (anti-IL-6Rα) (S412003) - SEC
The purity of Sarilumab (anti-IL-6Rα) (S412003) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0102631 | Certificate of Analysis | Jan 26, 2024 | S412003 |
| ZJ24F0102632 | Certificate of Analysis | Jan 26, 2024 | S412003 |
| ZJ24F0102633 | Certificate of Analysis | Jan 26, 2024 | S412003 |
| 1. Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y et al.. (2017) Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.. RMD Open, 3 (1): (e000416). [PMID:28326189] |
| 2. Boyapati A, Msihid J, Fiore S, van Adelsberg J, Graham NM, Hamilton JD. (2016) Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.. Arthritis Res Ther, 18 (1): (225). [PMID:27716324] |
| 3. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB. (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.. Ann Rheum Dis, 76 (5): (840-847). [PMID:27856432] |
| 4. Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M et al.. (2020) Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.. Ann Rheum Dis, 79 (10): (1277-1285). [PMID:32620597] |
| 5. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334] |
| 6. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K et al.. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs.. Nat Genet, 36 (1): (40-5). [PMID:14702039] |
| 7. Varghese JN, Moritz RL, Lou MZ, Van Donkelaar A, Ji H, Ivancic N, Branson KM, Hall NE, Simpson RJ. (2002) Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.. Proc Natl Acad Sci USA, 99 (25): (15959-64). [PMID:12461182] |
| 8. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.. Science, 300 (5628): (2101-4). [PMID:12829785] |
| 9. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L et al.. (2015) The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.. Arthritis Res Ther, 17 (3): (135). [PMID:25994180] |
| 10. Kang S, Tanaka T, Narazaki M, Kishimoto T. (2019) Targeting Interleukin-6 Signaling in Clinic.. Immunity, 50 (4): (1007-1023). [PMID:30995492] |
| 11. Li H, Xiao H, Lin L, Jou D, Kumari V, Lin J, Li C.. (2014) Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.. J Med Chem, 57 (3): (632-641). [PMID:24456369] |
| 12. Schooltink, H H and 7 more authors.. (1991) Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells.. The Biochemical journal, (1): [PMID:1872801] |
| 13. Novick, D D, Engelmann, H H, Wallach, D D and Rubinstein, M M.. (1989) Soluble cytokine receptors are present in normal human urine.. The Journal of experimental medicine, (1): [PMID:2529343] |
| 14. Yamasaki, K K and 8 more authors.. (1988) Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor.. Science (New York, N.Y.), (12): [PMID:3136546] |
| 15. Horiuchi, S S and 8 more authors.. (1994) Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism.. European journal of immunology, [PMID:8056053] |
| 16. Yawata, H H and 7 more authors.. (1993) Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130.. The EMBO journal, [PMID:8467812] |
| 17. Cole, A R AR and 6 more authors.. (1999) Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor.. The Journal of biological chemistry, (12): [PMID:10066782] |
| 18. Martens, A S AS, Bode, J G JG, Heinrich, P C PC and Graeve, L L.. (2000) The cytoplasmic domain of the interleukin-6 receptor gp80 mediates its basolateral sorting in polarized madin-darby canine kidney cells.. Journal of cell science, [PMID:11017875] |
| 19. Nakahara, Hideko H and 6 more authors.. (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.. Arthritis and rheumatism, [PMID:12794819] |
| 20. Buk, Deborah M DM, Renner, Olga O and Graeve, Lutz L.. (2005) Increased association with detergent-resistant membranes/lipid rafts of apically targeted mutants of the interleukin-6 receptor gp80.. European journal of cell biology, [PMID:16270750] |
| 21. Gregory, S G SG and 178 more authors.. (2006) The DNA sequence and biological annotation of human chromosome 1.. Nature, (18): [PMID:16710414] |
| 22. Smolen, Josef S JS and Maini, Ravinder N RN.. (2006) Interleukin-6: a new therapeutic target.. Arthritis research & therapy, [PMID:16899109] |
| 23. Reich, David D and 23 more authors.. (2007) Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels.. American journal of human genetics, [PMID:17357077] |
| 24. Betts, Brian C BC, St Angelo, Erin T ET, Kennedy, Michael M and Young, James W JW.. (2011) Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.. Blood, (10): [PMID:21940820] |
| 25. Huizinga, Tom W J TW and 9 more authors.. (2014) Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.. Annals of the rheumatic diseases, [PMID:24297381] |
| 26. and Lin, Phoebe P.. (2015) Targeting interleukin-6 for noninfectious uveitis.. Clinical ophthalmology (Auckland, N.Z.), [PMID:26392750] |
| 27. Lokau, Juliane J and 13 more authors.. (2016) Proteolytic Cleavage Governs Interleukin-11 Trans-signaling.. Cell reports, (23): [PMID:26876177] |
| 28. June, Rayford R RR and Olsen, Nancy J NJ.. (2016) Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.. Expert opinion on biological therapy, [PMID:27464017] |
| 29. Riethmueller, Steffen S and 23 more authors.. (2017) Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation.. PLoS biology, [PMID:28060820] |
| 30. Smolen, Josef S JS and 48 more authors.. (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.. Annals of the rheumatic diseases, [PMID:28264816] |
| 31. Larsen, Jakob Vejby JV and Petersen, Claus Munck CM.. (2017) SorLA in Interleukin-6 Signaling and Turnover.. Molecular and cellular biology, (1): [PMID:28265003] |
| 32. Kampan, Nirmala Chandralega NC and 5 more authors.. (2018) Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.. Current medicinal chemistry, [PMID:28707587] |
| 33. Spencer, Sarah and 37 more authors.. (2019) Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses.. The Journal of experimental medicine, (2): [PMID:31235509] |
